Palmitoylethanolamide treatment led to an improved clinical picture. - GreenMedInfo Summary
Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: a case report.
CNS Neurol Disord Drug Targets. 2012 Nov 1 ;11(7):933-6. PMID: 22998138
Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by progressive degeneration of motor neurons which leads to muscular atrophy, paralysis and death in 3-5 years from starting symptoms. This disorder is accompanied by noteworthy spinal inflammation mediated in particular by microglia and mast cells. No effective therapy is available. This report describes the effects of administering the anti-inflammatory agent palmitoylethanolamide in a case of sporadic amyotrophic lateral sclerosis. Palmitoylethanolamide treatment led to an improved clinical picture, as evidenced by electromyographic analysis and pulmonary function. Conceivably, the action of palmitoylethanolamide could result, in part, from its ability to dampen mast cell and microglia activation.